Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.45 |
| ▸ | SLK | Q9H2G2 | 5/20 | 0.43 |
| ▸ | STK10 | O94804 | 4/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4997476 | 0.77 | BRAF (0.64) | BRAFFYNABCG2 | |
| SCHEMBL1122131 | 0.73 | BRAF (1.00) | BRAF | |
| SCHEMBL5000792 | 0.73 | BRAF (0.55) | BRAFFYNABCG2 | |
| SCHEMBL4014599 | 0.72 | CDK2 (0.60) | BRAFABCG2EGFRERBB2 | |
| SCHEMBL14005487 | 0.71 | SYK (0.43) | ABCG2EGFRERBB2 | |
| SCHEMBL4992499 | 0.70 | BRAF (0.60) | BRAFFYNABCG2 | |
| SCHEMBL4997522 | 0.70 | BRAF (0.60) | BRAFABCG2 | |
| SCHEMBL18613337 | 0.69 | FYN (1.00) | BRAFFYN | |
| SCHEMBL4994977 | 0.68 | BRAF (0.74) | BRAF | |
| SCHEMBL3529729 | 0.67 | BRAF (0.71) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1694670-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC Biotech AG (DE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058876-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC BIOTECH AG (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | BRAF 478/4885FYN 20/4885AGPAT2 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.